TheraRadar

Pharma Intelligence, Simplified

Landscape → Infectious Disease

Tuberculosis

294 clinical trials

101 active
/
294 total (since 2015)
20
Phase 1 Active
86 total
43
Phase 2 Active
134 total
41
Phase 3 Active
81 total
14
Phase 4 Active
31 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. 3 10 1
Shanghai Jiatan Pharmatech Co., Ltd 3 1 0
Otsuka Pharmaceutical Development & Commercialization, Inc. 1 2 0
Biofabri, S.L 1 2 0
BioNTech SE 1 1 0
Chengdu CoenBiotech Co., Ltd 1 1 0
Bharat Biotech International Limited 1 1 0
BioVersys AG 1 0 0
Johnson & Johnson 1 0 0
WestVac Biopharma Co., Ltd. 1 0 0
CanSino Biologics Inc. 1 0 0
Quratis Inc. 1 0 0
GSK 0 4 1
Archivel Farma S.L. 0 2 2
Serum Institute of India Pvt. Ltd. 0 3 0
NCT06568484 NOT YET RECRUITING
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
Johns Hopkins University n=2,530
NCT06062238 ACTIVE NOT RECRUITING
Study to Assess Efficacy and Safety of M72/AS01E-4 Mycobacterium Tuberculosis (Mtb) Vaccine in Adolescents and Adults
Gates Medical Research Institute n=20,080
NCT07209761 RECRUITING
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
Otsuka Pharmaceutical Development & Commercialization, Inc. n=532
NCT06498414 RECRUITING
Shorter and Safer Treatment Regimens for Latent TB
McGill University Health Centre/Research Institute of the McGill University Health Centre n=1,800
NCT06057519 RECRUITING
Pragmatic Optimized Rifampicin Trial
Radboud University Medical Center n=164
NCT06441006 RECRUITING
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
University of California, San Francisco n=400
NCT07332325 NOT YET RECRUITING
STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis
University of Virginia n=344
NCT04951986 ACTIVE NOT RECRUITING
Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis
University of Cape Town n=732
NCT06022146 RECRUITING
TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts
Huashan Hospital n=3,520
NCT07268664 NOT YET RECRUITING
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort
Beijing Chest Hospital n=120
NCT06905522 RECRUITING
A PAN-USR TB Multi-Center Trial
Shenzhen Third People's Hospital n=610
NCT06253715 RECRUITING
Shortened Regimen for Drug-susceptible TB in Children
Johns Hopkins University n=860
NCT06497465 RECRUITING
Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
Johns Hopkins University n=150
NCT05766267 ACTIVE NOT RECRUITING
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Centers for Disease Control and Prevention n=288
NCT05473520 RECRUITING
Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
National University Hospital, Singapore n=150
NCT07163143 NOT YET RECRUITING
Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)
University College, London n=784
NCT07152639 RECRUITING
Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above
Chengdu CoenBiotech Co., Ltd n=1,784
NCT06649721 ACTIVE NOT RECRUITING
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
Huashan Hospital n=120
NCT07136987 NOT YET RECRUITING
A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery
Open Source Pharma Foundation n=1,104
NCT07118696 NOT YET RECRUITING
Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease
Hamilton Health Sciences Corporation n=1,000
NCT07076225 NOT YET RECRUITING
Ultra-Short Regimen for Elderly DS-TB
Shenzhen Third People's Hospital n=300
NCT05824871 RECRUITING
A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients
Shanghai Jiatan Pharmatech Co., Ltd n=450
NCT03568383 ACTIVE NOT RECRUITING
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
National Institute of Allergy and Infectious Diseases (NIAID) n=5,832
NCT05686356 ACTIVE NOT RECRUITING
A Pan-TB Regimen Targeting Host and Microbe
The Aurum Institute NPC n=352
NCT04260477 RECRUITING
Novel Triple-dose Tuberculosis Retreatment Regimen
Institute of Tropical Medicine, Belgium n=370
NCT05899179 RECRUITING
Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. n=780
NCT05081401 RECRUITING
Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
Huashan Hospital n=1,050
NCT06081361 ACTIVE NOT RECRUITING
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
Beijing Chest Hospital n=186
NCT06727864 RECRUITING
Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial
Kaohsiung Veterans General Hospital. n=270
NCT06191692 NOT YET RECRUITING
1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam
Freundeskreis Für Internationale Tuberkulosehilfe e.V n=350
NCT04975178 RECRUITING
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
Biofabri, S.L n=7,120
NCT06719193 RECRUITING
DeMONSTRATE-TB Study in Ethiopia
Management Sciences for Health n=131,438
NCT06618573 RECRUITING
Safety of Administering Isoniazid to SLE Patients to Prevent TB
Universitas Padjadjaran n=60
NCT03474029 RECRUITING
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
Centers for Disease Control and Prevention n=3,400
NCT04147286 RECRUITING
Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
University of Cape Town n=220
NCT06526039 NOT YET RECRUITING
A Short Regimen for Rifampicin-resistant Isoniazid-susceptible TB
Taipei Medical University WanFang Hospital n=100
NCT04856644 ACTIVE NOT RECRUITING
Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB
Kaohsiung Veterans General Hospital. n=333
NCT05401071 RECRUITING
Optimizing(O) RIfapentine-based(RI) Regimen and shortENing(EN) the Treatment of Drug-sensitive Tuberculosis(T)
Huashan Hospital n=2,442
NCT05575518 RECRUITING
A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
Stellah Mpagama n=414
NCT05454345 NOT YET RECRUITING
Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
First Affiliated Hospital of Zhejiang University n=620
NCT04485156 NOT YET RECRUITING
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
Seoul National University Hospital n=926
NCT04453293 TERMINATED
Immunization With BCG Vaccine to Prevent Tuberculosis Infection
Henry M. Jackson Foundation for the Advancement of Military Medicine n=16
NCT04738812 COMPLETED
Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression
ANRS, Emerging Infectious Diseases n=1,330
NCT03915366 COMPLETED
Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia
Hospital Universitario 12 de Octubre n=563
NCT02563327 COMPLETED
Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
Centers for Disease Control and Prevention n=53
NCT02333799 COMPLETED
A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB
Global Alliance for TB Drug Development n=109
NCT03100786 COMPLETED
Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis
Oxford University Clinical Research Unit, Vietnam n=702
NCT03152903 COMPLETED
Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence
Serum Institute of India Pvt. Ltd. n=2,000
NCT03896685 COMPLETED
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Médecins Sans Frontières, France n=323
NCT02754765 COMPLETED
Evaluating Newly Approved Drugs for Multidrug-resistant TB
Médecins Sans Frontières, France n=754
NCT04351685 COMPLETED
Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants
Serum Institute of India Pvt. Ltd. n=6,940
NCT02410772 COMPLETED
TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens
Centers for Disease Control and Prevention n=2,516
NCT04062201 COMPLETED
Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
Wits Health Consortium (Pty) Ltd n=402
NCT04121195 COMPLETED
Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load
University of Liverpool n=26
NCT02589782 COMPLETED
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
Medecins Sans Frontieres, Netherlands n=552
NCT04207112 COMPLETED
Economic Evaluation of New MDR TB Regimens
Medecins Sans Frontieres, Netherlands n=73
NCT03092817 COMPLETED
Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)
Oxford University Clinical Research Unit, Vietnam n=520
NCT03338621 COMPLETED
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
Global Alliance for TB Drug Development n=455
NCT04094012 COMPLETED
Risk of SDRs Under 3HP and 1HP Regimen for LTBI
National Taiwan University Hospital n=490
NCT05330884 SUSPENDED
BCG Revaccination in Children and Adolescents
Tuberculosis Research Centre, India n=9,200
NCT04721795 COMPLETED
Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)
Obafemi Awolowo University Teaching Hospital n=150
NCT02409290 COMPLETED
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
IUATLD, Inc n=588
NCT03474198 COMPLETED
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
University College, London n=675
NCT03086486 COMPLETED
Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis
Global Alliance for TB Drug Development n=181
NCT02581527 COMPLETED
A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis
St George's, University of London n=672
NCT03947138 COMPLETED
A Study of GC3107(BCG Vaccine) in Healthy Infants
Green Cross Corporation n=750
NCT02880982 COMPLETED
Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren
Queen Mary University of London n=1,743
NCT02454205 COMPLETED
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
University of Cape Town n=154
NCT03545373 COMPLETED
Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)
London School of Hygiene and Tropical Medicine n=1,583
NCT04285905 TERMINATED
Male Partner-assisted Contact Tracing for HIV and Tuberculosis in Malawi
Liverpool School of Tropical Medicine n=30
NCT02795260 COMPLETED
Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. n=1,802
NCT02276755 COMPLETED
Vitamin D Supplementation in TB Prevention
Harvard School of Public Health (HSPH) n=8,851
NCT02430259 COMPLETED
Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention
Huashan Hospital n=566
NCT03862248 WITHDRAWN
Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
Institute of Tropical Medicine, Belgium
NCT02980016 COMPLETED
Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals
The Aurum Institute NPC n=4,027
NCT02342886 COMPLETED
Shortening Treatment by Advancing Novel Drugs
Global Alliance for TB Drug Development n=284
NCT02273765 COMPLETED
Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis
ANRS, Emerging Infectious Diseases n=460
NCT03027154 COMPLETED
Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen for Children
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. n=96
NCT02623556 COMPLETED
Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. n=1,090
NCT02975570 WITHDRAWN
Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin
Boston University
NCT02845349 WITHDRAWN
Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)
Johns Hopkins University

Data: ClinicalTrials.gov